Encelimab

Encelimab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Encelimab (anti-LAG3)
CAS:2173096-82-5
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14636
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Encelimab
CAS:2173096-82-5
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Encelimab
CAS:2173096-82-5
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Encelimab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Encelimab(DHD30404)
CAS:2173096-82-5
Purity:PAGE:>95% Package:100ug;1mg
Encelimab Basic information
Product Name:Encelimab
Synonyms:Encelimab;Research Grade Encelimab(DHD30404);Research Grade Encelimab;Encelimab (anti-LAG3)
CAS:2173096-82-5
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Encelimab Structure
Encelimab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Encelimab Usage And Synthesis
UsesEncelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft)[1].
References[1] Perez-Santos M, et al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Dec;17(12):1341-1355. DOI:10.1080/17460441.2022.2148652
Encelimab Preparation Products And Raw materials
Tag:Encelimab(2173096-82-5) Related Product Information
Magrolimab Suvizumab Ocrelizumab Bemarituzumab Eptinezumab Varisacumab Zilovertamab Girentuximab Frovocimab Glofitamab